TLR4 and rheumatoid arthritis: NI-0101 is the first monoclonal anti-TLR4 antibody entering clinical development, which declared that could block rheumatoid arthritis (RA) synovial fluids-induced pro-inflammatory cytokine production (Hatterer et al., 2016).